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Abstract: Coronary artery calcium (CAC) is an integral part of atherosclerotic coronary 
heart disease (CHD). CHD is the leading cause of death in industrialized nations and there 
is a constant effort to develop preventative strategies. The emphasis is on risk stratification 
and primary risk prevention in asymptomatic patients to decrease cardiovascular mortality 
and  morbidity. The  Framingham  Risk  Score  predicts  CHD  events  only  moderately  well 
where family history is not included as a risk factor. There has been an exploration for new 
tests for better risk stratification and risk factor modification. While the Framingham Risk 
Score, European Systematic Coronary Risk Evaluation Project, and European Prospective 
Cardiovascular Munster study remain excellent tools for risk factor modification, the CAC 
score  may  have  additional  benefit  in  risk  assessment.  There  have  been  several  studies 
supporting the role of CAC score for prediction of myocardial infarction and cardiovascular 
mortality. It has been shown to have great scope in risk stratification of asymptomatic patients 
in the emergency room. Additionally, it may help in assessment of progression or regression 
of coronary artery disease. Furthermore, the CAC score may help differentiate ischemic from 
nonischemic cardiomyopathy.
Keywords: coronary calcium scoring, coronary artery disease, CAC, cardiomyopathy, 
angiography, chest pain, Framingham, risk stratification, risk factors
Background
Coronary heart disease (CHD) is the leading cause of death in industrialized   countries. 
Cardiovascular mortality in the US alone is close to a million per year. This problem is 
on the rise, in view of the increasing number of elderly people in the US and worldwide. 
By 2020, there will be more than 50 million people aged older than 65 years in the US 
alone. Continuous efforts are being made to develop preventative strategies for CHD. 
Cardiovascular risk stratification by primary risk assessment is a key step towards 
this goal. Traditional risk assessment is based on the Framingham Risk Score (FRS) 
which was developed based on clinical research in men and women from Framingham, 
  Massachusetts, followed over three generations. This evaluation was done to understand 
better the causes of cardiovascular disease. There have been at least 1973 publications 
in peer-reviewed journals up until 2008. This has led to risk factor stratification and 
modification measures in cardiovascular practice. This risk stratification is based on 
the Framingham Heart Study (FHS, see http://www.framinghamheartstudy.org) in 
the US, the European Systematic Coronary Risk Evaluation (SCORE) study,1 and the 
Prospective Cardiovascular Munster (PROCAM) study in Germany.2 Each of these 
studies documents a 10-year risk for cardiovascular events which dictates public Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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policies, and the intensity of treatment generally depends 
upon the risk stratification.
Cardiac risk assessment
Unfortunately, traditional risk factor assessment has a very 
poor sensitivity and specificity to predict coronary events. In 
the past, exercise stress testing was performed to diagnose 
coronary artery disease (CAD) in asymptomatic patients and 
it is not currently recommended as a screening test.3 At least 
25% of patients with CHD have asymptomatic presentation 
with nonfatal myocardial infarction (MI) or sudden death, 
and therefore there is a constant need for improvement of 
risk stratification measures.4 The American Heart   Association 
(AHA) Prevention V Conference emphasized going beyond 
secondary prevention and addressed ways to identify risk 
in asymptomatic patients to justify more intensive risk 
reduction.5
It is common to address this clinical risk assessment as 
an initial step and also recognize CHD risk equivalents, as 
shown in Tables 1 and 2. National Cholesterol Education 
Program (NCEP) guidelines have classified patients into 
different categories, depending upon the presence of CHD 
or risk factors for 10-year risk of fatal CHD or nonfatal MI, 
as illustrated in Table 3.
The NCEP targets high-risk groups for risk factor 
modification, and intermediate-risk groups may need further 
risk stratification. Furthermore, intermediate-risk groups may 
be deemed to be high-risk based on the presence of coronary 
artery calcium (CAC) requiring aggressive intervention. 
  Several investigators have investigated use of the CAC score 
to risk stratify patients further. Current clinical practice for 
risk stratification is based on several clinical guidelines.6,7
Each risk factor has points, and based on their accumulated 
points, patients fall into categories of low-, moderate-, to high-
risk groups for CHD. The risk score was developed based on 
risk factors such as total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), blood pressure, age, smoking, and 
gender. Based on these risk factor scores, the risk for CHD 
can be classified from low- to high-risk, and one can estimate 
the 10-year likelihood of developing a major cardiac event, 
as shown in Table 3. Low-risk CHD correlates with 10% 
mortality at 10 years, moderate-risk with 10%–20%, and 
high-risk with greater than 20% risk of mortality. This can 
readily be calculated by using an online Framingham risk 
calculator at http://hp2010.nhlbihin.net/ATPiii/calculator.
asp?usertype=prof; http://www.framinghamheartstudy.org/
risk/hrdcoronary.html.
Framingham heart study
The FRS uses traditional risk factors to predict risk of 
  coronary events in people without known CAD.8,9 This 
  cardiac risk assessment is based on the FHS, which is an 
ongoing study for more than 50 years leading to several 
publications. This historical study has participation of three 
generations, and a careful analysis of the initial cohort and 
subsequent two generations has led to identification of major 
cardiovascular risk factors. This had led to the achievement 
of several milestones in the management of cardiovascular 
disease. One of the milestones achieved in 1998 was risk 
prediction, with an algorithm based on the presence of various 
risk factors. There have been numerous discussions on FRS 
Table 1 Risk factors contributing to 10-year risk of CHD
• For patients with multiple (2+) risk factors
– Perform 10-year risk assessment
• For patients with 0–1 risk factor
– 10-year risk assessment not required
– Most patients have 10-year risk ,10%
Major risk factors
– LDL cholesterol
– Cigarette smoking
–   Hypertension (BP 140/90 mmHg or on antihypertensive medication)
– Low HDL cholesterol (,40 mg/dL)
– Family history of premature CHD
 •  CHD in male first-degree relative ,55 years
 •  CHD in female first-degree relative ,65 years
– Age (men 45 years, women 55 years)
–   HDL cholesterol 60 mg/dL counts as “negative” risk factor; its 
presence removes one risk factor from the total count
– In ATP III, diabetes is regarded as a CHD risk equivalent
Abbreviations: ATP iii, Adult Treatment Panel iii; CHD, coronary heart disease; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; BP, blood pressure.
Table 2 Coronary heart risk equivalents
• Clinical forms of atherosclerotic disease
–   (peripheral arterial disease, abdominal aortic aneurysm, and 
symptomatic carotid artery disease)
– Diabetes
–   Multiple risk factors that confer a 10-year risk for coronary heart 
disease .20%
Table 3 Framingham risk score
•   Risk score . 20%: High-risk range, with a greater than 20% risk of 
heart attack or death from coronary disease in the next 10 years. This 
risk can be reduced by addressing the risk factors
•   Risk score 10%–20%: Intermediate-risk range, with a 10%–20% risk of 
heart attack or death from coronary disease in the next 10 years. This 
risk can be reduced
•   Risk score , 10%: Low-risk range, with less than 10% risk of heart 
attack or death from coronary disease in the next 10 yearsVascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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calculation on risk assessment in asymptomatic patients 
which can be found on the Framingham website and the 
National Heart Lung and Blood Institute websites. The risk 
score classifies patients into high-risk, intermediate-risk, and 
low-risk for CHD, as shown in Table 3.
european PROCAM study
In the US, the FHS provides the extensively validated risk 
assessment by a multivariable scoring system for major 
cardiovascular endpoints. This scoring system includes major 
risk factors such as age, gender, total cholesterol, HDL-C, 
hypertension (or on treatment for hypertension), and cigarette 
smoking. While family history was not included as a risk 
factor in FHS, other studies, ie, SCORE and PROCAM,1,2 
have included age, gender, low-density lipoprotein cholesterol 
(LDL-C), HDL-C, triglycerides, systolic blood pressure (BP), 
cigarette smoking, family history of premature CHD, and pres-
ence or absence of diabetes mellitus. PROCAM was a large 
epidemiological cohort study, developed from data for more 
than 26,000 subjects in Germany over a period of 25 years2 
which helped to develop a cardiovascular risk calculator. Risk 
can be calculated on the PROCAM website by a simplified 
version of the PROCAM risk calculator, which is an Interna-
tional Task Force for Prevention of Coronary Heart disease 
(http://www.chd-taskforce.com/procam_interactive.html).
european SCORe study
SCORE was developed for cardiovascular risk stratification 
in European clinical practice to calculate the 10-year risk for 
CHD and noncoronary cardiovascular disease. This score 
system was based on data collected from a large cohort of 
205,178 subjects from 12 European countries.1
wHO MONiCA project
The concept of risk stratification was born after the FHS. There 
was a need for long-term monitoring of mortality, morbidity, 
and risk factors in clinical practice. The Multinational 
Monitoring of Trends and Determinants in Cardiovascular 
Diseases (MONICA)10 project was established to monitor 
trends in cardiovascular disease around the world. This 
project showed major changes in survival, driven by changes 
in coronary event rates, which further emphasize the need 
for risk factor modification tools.
Incremental risk stratification  
by CAC score
While the FRS and PROCAM remain excellent tools for 
risk factor modification, the CAC score may have additional 
  benefit in risk assessment. Atherosclerotic plaque passes 
through several stages of plaque rupture and healing, 
  followed by calcification. Thus, the presence of calcium 
can be considered an advanced marker of CHD. There have 
been numerous studies supporting the role of CAC score for 
prediction of MI and cardiovascular death. CAC clearly adds 
to the predictive value of traditional risk factors. While spotty 
calcification has been considered a marker of vulnerable 
plaque,11 the relationship between the presence and amount 
of calcium in an individual coronary artery found on coronary 
angiography to predict cardiovascular events is uncertain.12 
It is most likely that the co-occurrence of calcified and non-
calcified plaques may determine progression of CHD.13
Role of CAC score in primary 
prevention
In 1996 and subsequently in 2000, AHA consensus 
documents14,15 have stated that “CAC is a part of development 
of CAD and occurs exclusively in atherosclerotic CAD and 
is absent in normal arteries”. CAC plaque documents the 
presence of CAD in an individual patient as compared with 
just the presence of risk factors. Detection of asymptomatic 
CAD has been of great interest since the publication of 
the Screening for Heart Attack Prevention and Education 
(SHAPE).16 Moreover, detection of vulnerable plaque leading 
to coronary events is of paramount importance. The role of 
CAC in identification of vulnerable plaque is unknown.17 
Spotty calcification has been shown to identify patients with 
vulnerable plaque.11 This may be due to noncalcified plaque 
on the shoulders of calcified plaque.
CHD risk assessment with CAC 
score in asymptomatic patients
The important risk factor, ie, positive family history, is not 
included in risk stratification by the FRS. Because FRS pre-
dicts CHD events only moderately well, there has been an 
exploration for better risk stratification tests so that patients 
may benefit from aggressive risk factor modification.5–7 This 
can be accomplished by CAC scoring. There have been a 
large number of studies showing the prognostic value of 
the CAC score in 2000–2009,18–24 leading to great interest 
in this score.
While initially there were conflicting data about the 
prognostic value of the CAC score, this was addressed by 
Arad et al in 2000 in 1172 subjects by multivariate analysis.25 
The purpose of this study was to evaluate the prognostic 
accuracy of a high CAC score with electron-beam computed 
tomography (CT). During an average 3.6 year follow-up in Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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this study, 39 subjects had coronary events, which included 
nonfatal MI in 15, coronary artery revascularization in 21, 
and coronary death in three. Based on these data, it was 
concluded that electron-beam CT predicts coronary events. 
Kondos et al26 also demonstrated the added value of CAC 
score in a largest retrospective study of 8855 self-referred 
men and women without prior cardiovascular events. Follow-
up was available in 5634 (64%) at 37 ± 13 months for 4151 
men and 1484 women, and showed incremental prognostic 
information in addition to conventional risk factors.
Greenland et al20 examined the incremental prognostic 
value of the CAC score in addition to traditional risk factors 
in a prospective observational study. This was a population-
based study of 1461 asymptomatic adults with traditional 
coronary risk factors assessed by FRS. These participants 
were screened from 1990–1992 and had initial FRS and CAC 
scores. They were contacted yearly up to 8.5 years after the 
initial CAC test for nonfatal MI and/or CHD-related death. 
This study evaluated whether FRS and CAC score predicted 
all-cause mortality, which was stratified by four levels of 
FRS and four levels of CAC score, as illustrated in Figure 1. 
FRS categories are the estimated 10-year risk of CHD (death 
or nonfatal MI) events based on FRS. In this study, CAC 
score alone was able to predict CHD risk independently of 
FRS. Moreover, CAC score significantly modified the risk 
prediction in all categories of FRS category with risk .10% 
(ie, 10-year risk of CHD events .10%).
Another large study by Lamont et al24 reported a follow-up 
on 11,000 patients who underwent screening medical 
examination including CAC score during 1995–2000. In a mean 
follow-up of 3.5 years in asymptomatic men and women, CHD 
events (nonfatal MI and CHD-related deaths) were higher with 
a CAC score .400. The Prospective Army Coronary Calcium 
Project (PACC)22 showed the independent prognostic value of 
CAC score in young asymptomatic men and women of mean 
age 43 years. This study showed that the presence of CAC was 
associated with an 11.8-fold increased risk of coronary events 
in a three-year follow-up of men aged 40–45 years.
The Rotterdam Coronary Calcification Study23 addressed 
the role of the CAC score in elderly patients. This was a pro-
spective, population-based study in 1795 patients comparing 
patients with CAC ,100 with those having CAC of 101–400, 
CAC 401–1000, and CAC .1000. CAC score was found to 
be a strong and independent predictor of future events, as 
illustrated in Figures 2 and 3. Different CAC score categories 
also predicted survival free of a CHD event and cardiovas-
cular disease events, as shown in Figure 3.
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Figure 1 Predicted seven-year event rate from Cox regression model for CHD death 
or nonfatal MI for different categories of FRS or CAC score. The event rates are 
stratified by four levels of FRS and four different levels of calcium score. Analysis showed 
a statistically significant difference between and calcium score .300 and other groups 
for FRS categories .10% CHD risk. Copyright © 2004, American Medical Association. 
All rights reserved. Adapted with permission from Greenland P, LaBree L, Azen SP, 
Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham 
score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–215.
Abbreviations:  CACS,  coronary  artery  calcium  score;  CHD,  coronary  heart 
disease; FRS, Framingham Risk Score; MI, myocardial infarction.
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Figure  2  event  rate  according  to  calcium  score  category.  Copyright  ©  2005, 
American Heart Association. All rights reserved. Adapted with permission from 
Vliegenthart  R,  Oudkerk  M,  Hotman  A,  et  al.  Coronary  calcification  improves 
cardiovascular risk prediction in the elderly. Circulation. 2005;112(4):572–577.
Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; FRS, 
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Bild et al27 showed that CAC is influenced by age,   gender, 
and ethnicity. The role of CAC score in different ethnic groups 
for incremental risk prediction was examined in the Multi-
Ethnic Study of Atherosclerosis (MESA).28 MESA was a 
population-based study which enrolled subjects of four differ-
ent ethnic groups from six sites across the US. Data on CHD 
risk factors and CAC scores in different ethnic groups were 
followed for an average period of 3.8 years. Patients had com-
prehensive risk assessment with every possible test and were 
followed from 2000 onwards. This study showed that doubling 
of CAC score increased the risk of a major cardiovascular 
event, such as death and MI. Risk of any coronary events or 
major events was independent of other risk factors. CAC score 
was found to be highly predictive of cardiovascular risk in all 
the four ethnic groups and it contributed to the risk of both 
major coronary events (Figure 4, Panel A) and any coronary 
events (Figure 4, Panel B). CAC score alone was better than 
all the other risk factors combined for risk prediction.
This clearly demonstrated that CAC score is a strong 
predictor for the risk of developing clinical CHD. It pro-
vides a risk prediction beyond the standard risk prediction 
of the FRS. This risk prediction by CAC scoring was also 
demonstrated in different ethnic groups, including white, 
black, Hispanic, and Chinese in the MESA trial. Based on 
this study, there is a risk calculator based on age, gender, 
ethnicity and other risk factors, known as the MESA risk 
calculator, where an individual’s CAD risk can be calculated 
relative to that of peers (http://www.mesa-nhlbi.org/Calcium/
input.aspx).
Role of CAC in symptomatic 
patients
In symptomatic patients, the CAC score has been evaluated 
as a noninvasive tool to diagnose obstructive CAD, and this 
was published as an ACC/AHA consensus document.29,30 
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rates for any coronary event. Differences between all curves are statistically significant. 
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This document examined 3683 symptomatic patients in 
16   studies for evaluation of diagnostic accuracy of CAC 
scoring in patients referred for cardiac catheterization. Higher 
CAC score increased the likelihood of detecting significant 
CAD with greater than 50% stenosis. Guerci et al31 showed 
the relationship of CAC score to CAD in 290 symptomatic 
patients undergoing cardiac catheterization for approved 
clinical indications. A CAC score of 80 was not associated 
with any likelihood of CAD, regardless of number of risk 
factors and a CAC of 170 or more was associated with 
an increased likelihood of obstructive CAD (P , 0.001). 
Similarly,   Kennedy et al have shown that CAC score had 
a correlation with the extent of CAD, and was found be a 
better discriminator than other risk factors. A substudy from 
the MESA cohort analyzed the relationship between extent 
of CAC and severity of stenosis, and showed a significant 
association between the extent of CAC and mean degree 
of stenosis in individual coronary vessels.32 Schmermund 
et al33 also showed the CAC score to be a better discriminator 
which improved diagnostic accuracy over conventional risk 
factors. A multicenter trial in 1851 patients reported the role 
of ultrafast CT for diagnosis of CAD in symptomatic patients 
who underwent cardiac catheterization. In this study, a CAC 
score of 80 or more had a sensitivity of 79% and specificity 
of 72%,34 whereas the other large study35 used a cutoff CAC 
score of 100, leading to improved sensitivity of 95% and 
specificity of 79%.35 Nieman et al36 investigated the value of 
CAC detection on CT coronary angiography in comparison 
with exercise testing and CT coronary angiography to detect 
obstructive CAD. This study showed that lack of coronary cal-
cium was a reliable means to exclude obstructive CAD.36
Role of CAC score in the 
emergency room
Absence of CAC or minimal CAC predicted a very 
low incidence of future cardiac events in asymptomatic 
patients,18,25,37,38 symptomatic patients, and symptomatic 
patients undergoing cardiac catheterization.39,40 Several 
studies have shown the value of the CAC score in emergency 
room (ER) patients with a negative electrocardiogram (ECG) 
and negative cardiac enzymes as a triage tool with a very 
high negative predictive value.41,42 Georgiou et al42 per-
formed electron beam CT in 192 patients with chest pain 
and then followed them up for 50 ± 10 months. Among 
this cohort, 30% showed a graded relationship between 
all cardiac events and CAC score. This study showed that 
CAC score used as a triage test had a sensitivity of 97% and 
a negative predictive value of 99%. Patients without CAC 
(zero score) had a 0.6/year future cardiovascular event rate. 
Furthermore, recent studies have shown that CAC score may 
be a useful tool in the ER for risk stratification of patients 
with an acute coronary syndrome. Several other studies have 
demonstrated a significant correlation between CAC score 
and overall coronary artery atherosclerotic plaque, with a 
high sensitivity .95% and a high negative predictive value 
of .95%.13,43–45
Role of CAC score in triage  
of chest pain
Several studies have shown that CAC score may be a rapid 
and effective triage tool in ER patients with chest pain and 
nonspecific ECG abnormalities.41,42 The high sensitivity 
and high negative predictive value of the CAC score may 
allow early discharge of such patients. One study with long-
term follow-up showed that a CAC of zero represented a 
very low risk for cardiovascular events.42 Therefore, absence 
of CAC may be used as an effective screening tool before 
undertaking invasive coronary angiography. A CAC score of 
less than 100 predicts a low risk, with a less than 2% chance 
of an abnormal perfusion nuclear study,46,47 and a less than 
3% probability of obstructive CAD.34,35
CAC score to evaluate progression 
or regression
Does modulation of cardiac risk factors translate into 
regression of CAC score? Pathological studies have showed 
that a positive CAC score represents calcium in plaque which 
is an end result of healing of ruptured plaque. The process 
is complex, and drug therapy may have the potential to alter 
this fundamental process of calcification in the progression 
of atherosclerotic plaque. There are several factors in the 
progression of CAD, and the CAC score may be of biologic 
relevance. Serial CAC scoring may help monitor plaque 
regression by medical therapy.48 One needs to be mindful 
about the intertest variability in CAC score and have 
confidence in this to monitor regression or progression. 
Many studies have shown interscan variability of CAC score 
by 25%–50%,49–51 but using the same protocol this can be 
reduced to 10%–15%.51,52 Given that the annual progression 
of CAC is about 20%,49–51 the standard protocol will allow 
the detection of progression. This may have a bearing on 
management of the intermediate-risk group category with 
a high CAC score.
Several reports have shown CAC progression associated 
with increased risk of cardiovascular events and a stable 
CAC score associated with lower risk of cardiovascular Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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events.19,53,54 In the presence of definite CAC score progres-
sion (.15%) there was a significant relative risk of MI 
compared with patients having a stable score. Based on these 
findings, a serial CAC score is an attractive strategy for moni-
toring progression or regression of CAD. CAC regression has 
been demonstrated with pharmacologic interventions such 
as statins.55 Due to both cost issues and radiation concerns, 
serial monitoring of progression or regression of CAD using 
CAC scoring is not recommended at this time.
CAC score in diagnosis  
of cardiomyopathy
Technical ease and standardization of CAC score may play 
a role in the evaluation of the etiology of   cardiomyopathy. 
Clinical manifestations of ischemic and nonischemic 
  cardiomyopathy are similar and often require invasive 
testing, such as cardiac catheterization for final diagnosis. 
The role of electron beam CT was tested in a prospective, 
double-blind study56 with a 99% sensitivity for ischemic 
cardiomyopathy. The specificity for nonischemic cardio-
myopathy was 92% for a CAC score of ,80% and 83% for 
a CAC score of zero.
Technique and radiation issues
Radiographically, CAC provides an estimate of CAD burden. 
The most frequently used measure of CAC in the literature is 
the Agatston score57 which measures the amount of calcium 
in each lesion. Total CAC is the sum of the scores of all the 
calcified lesions in all the vessels.
This could be done with electron-beam CT or multi-detector 
CT available in most hospitals. There is no difference in CAC 
measured by electron-beam CT or multi-detector CT.58 A 
stack of cardiac images are obtained in an axial mode and 
calcified plaque is identified. This calcified plaque image is 
seen as white dots which are picture elements or pixels with 
an underlying number called Hounsfield Units (HU). Based 
on the HU numbers assigned to a pixel and its volume, we 
arrive at a CAC score. Just like a value for hypertension, a HU 
value above 129 is considered dense enough to call it calci-
fied and a weight factor is assigned, based on this number, 
to quantify the density. It is a simple procedure whereby the 
patient is brought into the room, placed in the scanner, and 
the whole heart is scanned. The patient goes through few 
breathing exercises and there is no need to have heart rate 
control for the test. Images with a slice thickness of 2.5 mm 
are obtained with either triggered or prospective ECG gat-
ing. With the prospective gating the radiation is as low as 1 
milliSievert (mSv).
Radiation exposure
Radiation exposure during CAC scoring is as low as 
1.0–1.3 mSv with electron-beam CT59 and 3 mSv with 
  multi-detector CT using retrospective gated scanning, which 
could be reduced to 1 mSv in prospective gating by multi-
detector CT.60 Any amount of radiation should be a concern 
and the “as low as reasonably achievable” (ALARA) principle 
should be used. This fact is underscored by a recent publication 
whereby current CT scan use for various studies is expected 
to contribute to a large number of future malignancies, which 
were estimated to be up to 29,000 on the basis of all the CT 
scans done in 2007.61 Given the carcinogenic potential of 
radiation, health care workers who prescribe it must be fully 
aware of radiation risks. They should have a full understanding 
of the effective dose concept which is a standard of measure 
of exposure expressed in mSv. Effective dose is the sum of 
weighted equivalent doses in all the organs and tissues during 
a particular scan. Due to higher doses delivered to lungs and 
female breast in coronary CT angiography, there is a higher 
carcinogenic effect on these organs. This risk is higher in 
younger patients and more in women than in men.
Summary
CAC is an integral part of development of CAD. Therefore, 
CAC scoring may be a valuable noninvasive imaging modality 
to do cardiac risk stratification in asymptomatic patients for 
cardiovascular risk. It is uncertain if CAC scoring will be cost-
effective in a population-based strategy. However, it certainly 
helps clinicians in the aggressive management of CAD in 
asymptomatic patients. The CAC score is a strong predictor of 
CHD incidence, and provides predictive information beyond 
the traditional risk factors in different ethnic groups.
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